Vectura is not saying which international pharmaceutical company’s US division has entered into a “collaboration, development, and license agreement” for the VR315 dry powder inhaler. VR315 is a fixed dose combination therapy for asthma and COPD, delivered using the Gyrohaler DPI.
The new partner will develop, manufacture, and commercialize the product in the US in a deal that includes a $10 million upfront payment to Vectura and up to $35 million in additional milestone payments, plus royalties. Sandoz licensed European and US rights to the product in 2006 but returned the US rights in March 2010. Sandoz retains European rights.
Vectura Chief Executive Chris Blackwell commented: “This deal provides Vectura with an excellent partner, with a strong track record in respiratory product development and commercialisation, committed to the successful development of VR315 for the lucrative US market. This is a major endorsement of the potential value of this product, Vectura’s technology and product development expertise.”
Read the Vectura press release.
